OKYO News and Press, OKYO Pharma Limited From 09/08/22

NEW YORK, NY / ACCESSWIRE / September 8 2022 / OKYO Pharma Limited (NASDAQ:OKYO); (LSE:OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that an interview with its CEO, Dr Gary Ja...

LONDON and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is pleased to announce that at the Annual General Meeti...

OKYO Pharma ( NASDAQ: OKYO ) said on Tuesday it plans a Q4 IND filing for OK-101 to treat dry eye disease with AmbioPharm. OK-101 is designed to increase the potency and combat ocular washout through the inclusion of the lipid 'anchor' contained in the molecule to enhance the ...

OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain. Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential. IND filing on OK-101 to treat DED planned for Q4 2022, with first human tria...

OKYO Pharma press release ( NASDAQ: OKYO ): FY total comprehensive loss of £3,976k (2021: £2,994k) Cash balance at 31 March 2022 £2,056k (31 March 2021: £4,992k). For further details see: OKYO Pharma reports FY results

LONDON and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO) (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2022. Summary of OKYO-101 studies during the last ...

LONDON and NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, today announces that it has been notified that Willy Simon, a non-executive d...